
DOSAGE AND ADMINISTRATION

DOSING AND PREMEDICATION IN PATIENTS WITH RELAPSED OR REFRACTORY B-ALL¹

TREATMENT CYCLES

- A single cycle of treatment consists of 4 weeks of continuous IV infusion followed by a 2-week treatment-free interval
- A treatment course consists of up to 2 induction cycles of BLINCYTO[®], followed by up to 3 consolidation cycles



PREMEDICATION

Intrathecal chemotherapy prophylaxis is recommended before and during BLINCYTO® therapy to prevent CNS ALL relapse.

Adult relapsed or refractory B-ALL patients should be premedicated with 20 mg IV dexamethasone 1 hour prior to initiation of each cycle to help minimise infusion reactions.

Paediatric relapsed or refractory B-ALL patients should be premedicated with dexamethasone 10 mg/m² (not to exceed 20 mg) orally or intravenously 6–12 hours prior to the start of BLINCYTO[®] (cycle 1 day 1), followed by premedication with dexamethasone 5 mg/m² orally or intravenously within 30 minutes of the start of BLINCYTO[®] (cycle 1 day 1).

PRE-PHASE TREATMENT FOR PATIENTS WITH HIGH TUMOUR BURDEN

For patients with \geq 50% leukaemic blasts or >15,000/mcL peripheral blood leukaemic blast counts treat with dexamethasone (not to exceed 24 mg/day).

HOSPITALISATION

- Hospitalisation is recommended at a minimum for the first 9 days of the first treatment cycle and the first 2 days of the second cycle
- For all subsequent cycle starts and reinitiation (e.g. if treatment is interrupted for ≥4 hours), supervision by a healthcare professional or hospitalisation is recommended

DOSAGE AND ADMINISTRATION

VOLUME CALCULATIONS IN PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WEIGHING ≥45 KG¹

IV BAGS	-24 h-		-48 h-		-72 h-		-96 h-	
Infusion time (rate)	24 hours (10 mL/h)		48 hours (5 mL/h)		72 hours (3.3 mL/h)		96 hours (2.5 mL/h)	
Dose (per day)	9 mcg	28 mcg	9 mcg	28 mcg	9 mcg	28 mcg	9 mcg	28 mcg
Number of reconstituted BLINCYTO [®] vials needed				××				
Volume of reconstituted BLINCYTO [®] required	0.83 mL	2.6 mL	1.7 mL	5.2 mL	2.5 mL	8 mL	3.3 mL	10.7 mL

250 ML CASSETTES

	-24 h-		-48 h-		-72 h-		-96 h-	
Cassette duration	24 hours		48 hours		72 hours		96 hours	
Dose (per day)	9 mcg	28 mcg						
Number of reconstituted BLINCYTO [®] vials needed								
Volume of reconstituted BLINCYTO [®] required	0.75 mL	2.3 mL	1.5 mL	4.7 mL	2.25 mL	7 mL	3 mL	9.3 mL

DOSAGE AND ADMINISTRATION


VOLUME CALCULATIONS IN PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WEIGHING <45 KG¹

IV BAGS	-24 h-		-48 h-		-72 h-		-96 h-	
Infusion time (rate)	24 hours (10 mL/hour)		48 hours (5 mL/hour)		72 hours (3.3 mL/hour)		96 hours (2.5 mL/hour)	
Dose (per day)	5 mcg/m ²	15 mcg/m ²	5 mcg/m ²	15 mcg/m ²	5 mcg/m ²	15 mcg/m ²	5 mcg/m ²	15 mcg/m ²
Number of reconstituted BLINCYTO [®] vials needed				to		to		to
Volume of reconstituted BLINCYTO [®] required for BSA 0.4–1.59 m ^{2†}	0.2–0.7 mL	0.6–2.1 mL	0.4–1.4 mL	1.2–4.2 mL	0.6–2.1 mL	1.8–6.3 mL	0.8–2.8 mL	2.4–8.3 mL

250 ML CASSETTES

Volume of reconstituted BLINCYTO® required for

BSA 0.4-1.59 m^{2†}



0.19-0.65

mL

0.56-1.9

mL

0.37-1.3

mL

1.1-3.9

mL

0.56-1.9

mL

1.7-5.8

mL

0.74-2.6

mL

2.2-7.7

mL



For more information on BLINCYTO[®] or to report any adverse events or product complaints involving BLINCYTO[®] please contact Australia Medical Information on 1800 803 638

> **PBS Information:** Section 100 listed. Authority required. Refer to PBS Schedule for full Authority listing.

REFER TO FULL PRODUCT INFORMATION BEFORE PRESCRIBING; AVAILABLE FROM AMGEN AUSTRALIA PTY LTD, PH: 1800 803 638 OR AT WWW.AMGEN.COM.AU/BLINCYTO.PI For more information about BLINCYTO[®] or to report an adverse event or product complaints about BLINCYTO[®], please contact Amgen Medical Information on 1800 803 638.

BLINCYTO® Minimum Product Information: Indication: treatment of relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (ALL); treatment of minimal residual disease (MRD) positive ALL in patients in complete haematological remission. Contraindications: hypersensitivity to blinatumomab, CHO-derived proteins or any excipient. Precautions: neurologic events; increased risk for serious infections; cytokine release syndrome; infusion reactions; tumour lysis syndrome, pancreatitis. Management of these adverse reactions may require interruption or discontinuation of treatment. Neutropenia and febrile neutropenia; elevated liver enzymes; leukoencephalopathy; medication errors - strictly follow preparation and administration instructions. Pregnancy Category: C. Use contraception during and for 48 hours after treatment. Discontinue breast-feeding during and for at least 48 hours after treatment. Do not use recommended adult fixed dose in paediatric patients. No data in patients aged less than 28 days. Interactions: low potential of clinically meaningful drug interaction with BLINCYTO® mediated cytokine elevation. Vaccination with live viral vaccines not recommended 2 weeks prior to or during treatment, and until recovery of B lymphocytes to normal range following last treatment cycle. Adverse Reactions: Common: infections, pyrexia, infusion-related reactions, headache, anaemia, febrile neutropenia, neutropenia, thrombocytopenia, oedema, increased liver enzymes, fatigue, nausea, tremor, hypokalaemia, diarrhoea, chills. See also Precautions for serious adverse reactions. Dosage & Administration: <u>R/R ALL</u>: Single cycle is 4 weeks continuous intravenous (cIV) infusion then 2 week treatment free interval. For patients greater than or equal to 45 kg (fixed dose): Cycle 1 - starting dose 9 micrograms/day for days 1-7, then 28 micrograms/day for days 8-28. All other cycles 28 micrograms/day for 4 weeks. For patients less than 45 kg (body surface area based dose): Cycle 1 - starting dose 5 micrograms/m²/day for days 1-7 (do not exceed 9 micrograms/ day), then 15 micrograms/m²/day (do not exceed 28 micrograms/day); all other cycles, 15 micrograms/m²/day (do not exceed 28 micrograms/day). For maintenance, 28 day cIV infusion, then 56 days treatment free. Hospitalise at least first 9 days of Cycle 1 and first 2 days of Cycle 2. Supervision or hospitalisation for other cycle starts and reinitiation. Adults: premedicate with 20 mg IV dexamethasone prior to initiation of each cycle. Intrathecal chemotherapy prophylaxis recommended before and during therapy. Treat with dexamethasone (< 24 mg/day) if high tumour burden. Paediatrics: premedicate with dexamethasone 10 mg/m2 (not to exceed 20 mg) oral or IV 6 to 12 hours prior to start of BLINCYTO[®] (Cycle 1 day 1), followed by premedication with dexamethasone 5 mg/m² oral or IV within 30 minutes of start of BLINCYTO[®] (Cycle 1 day 1). MRD+ ALL: 28 day cIV infusion then 14 days treatment free, for up to 4 cycles; premedicate with prednisone 100 mg IV or equivalent 1 hour prior to start of BLINCYTO® each cycle; hospitalise first 3 days Cycle 1 and first 2 days Cycle 2, supervise/hospital for subsequent cycle starts and reinitiation - see full PI. R/R & MRD + ALL - Interrupt BLINCYTO® if grade 3 neurological events, Cytokine Release Syndrome or other clinically relevant adverse reactions occur see full PI.



©2020 Amgen Australia Pty Ltd. ABN 31 051 057 428. Level 7, 123 Epping Road, North Ryde NSW 2113. Tel: 61 2 9870 1333, www.amgen.com.au. AU-12599. AMG3575-N. Prepared February 2020.

